Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06700343 · ClinicalTrials.gov registry record · Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
A Phase 3 study of Relapsing-remitting Multiple Sclerosis (RRMS), sponsored by Amgen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 444
- Enrollment target
- 20
- Study locations
NCT06700343 is a Phase 3 study of Relapsing-remitting Multiple Sclerosis (RRMS) that is actively recruiting participants, run by Amgen. The registered enrollment target is 444 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT06700343, a Phase 3 study of Relapsing-remitting Multiple Sclerosis (RRMS), is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 444 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizumab (EU), and to demonstrate pharmacodynamics (PD) similarity between ABP 692 and Ocrelizumab reference product (RP) based on assessment of the suppression of new active brain lesions over 24 weeks as assessed by magnetic brain imaging (MRI).
Conditions Studied
Interventions
- DRUG Ocrelizumab (US)
- DRUG Ocrelizumab (EU)
- DRUG ABP 692
Study Locations (20)
Florida
- Neurology Offices of South Florida - Boca Raton
- Aqualane Clinical Research - Naples
- Knight Neurology - Rockledge
- Premiere Research Institute Palm Beach - West Palm Beach
Colorado
- Mountain Neurological Research Center - Basalt
- Advanced Neurosciences Research, Llc - Fort Collins
Michigan
- Henry Ford Health - Detroit
- Michigan Institute For Neurological Disorders (Glendale Neurological Associates) - Farmington Hills - Farmington
New Jersey
- JFK Medical Center - Edison
- Hackensack Meridian Health - Paramus
Ohio
- Singlepoint Healthcare Opco, LLC - Columbus
- NDx Clinical Research, Inc - Dayton
Alabama
- University of South Alabama - Mobile
Arizona
- Clinical Endpoints, LLC - Scottsdale
California
- Profound Research - Neurology Center of Southern California - Carlsbad
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2025-01-13 |
| Est. Completion | 2027-12-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06700343
The ClinicalTrials.gov registry entry for NCT06700343 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 444 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsing-remitting Multiple Sclerosis (RRMS) appearing as the primary indexed condition, and to 3 interventions - of which Ocrelizumab (US) is the first listed.
NCT06700343 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Colorado, Michigan.
Frequently Asked Questions
What is clinical trial NCT06700343 about?
NCT06700343 is a clinical study titled "Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)". The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizumab (EU), and to demonstrate pharmacodynamics (PD) similarity between ABP 692 and Ocrelizumab reference product (RP) based on assessment of the suppressi...
What is the current status of trial NCT06700343?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 444 participants. The study started on 2025-01-13. Estimated completion is 2027-12-17.
What conditions does trial NCT06700343 study?
This clinical trial studies the following conditions: Relapsing-remitting Multiple Sclerosis (RRMS).
What interventions are being tested in trial NCT06700343?
The interventions under investigation include: Ocrelizumab (US) (DRUG), Ocrelizumab (EU) (DRUG), ABP 692 (DRUG).
Who is sponsoring clinical trial NCT06700343?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06700343 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing-remitting Multiple Sclerosis (RRMS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.